Multicenter, Double‐Blind, Randomized Trial of Emricasan in Hepatitis C–Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis

Ethan M. Weinberg,Michael P. Curry,Catherine T. Frenette,Fredric G. Regenstein,Eugene R. Schiff,Zachary D. Goodman,James M. Robinson,Jean L. Chan,Joanne C. Imperial,K. Rajender Reddy

DOI: https://doi.org/10.1002/lt.25934

2020-12-29

Liver Transplantation

Abstract:BackgroundDespite achieving sustained virologic response (SVR) to HCV therapy there remains a population of HCV patients post liver transplantation with advanced fibrosis or cirrhosis. Emricasan is an orally active, pan‐caspase inhibitor which suppresses apoptosis and inflammation and therefore potentially decreases inflammation and fibrosis. AimTo determine the safety and efficacy of emricasan in reducing or preventing progression of hepatic fibrosis in post‐transplant HCV recipients achieving SVR with anti‐viral therapy, and assess changes from baseline in ALT and caspases 3/7. Methods and PatientsStudy IDN‐6556‐07 was a double‐blind, randomized, placebo‐controlled, multicenter study in liver transplant recipients with chronic HCV who had SVR but had residual HCV‐related liver fibrosis or cirrhosis. Sixty‐four subjects were randomized to receive 25 mg twice daily of emricasan or placebo in a 2:1 ratio for 24 months. Results41 emricasan and 23 placebo subjects were randomized and 32 emricasan (78.0%) and 19 placebo (82.6%) subjects completed the study. There was no difference in the primary endpoint (Ishak F2‐F5, improvement in fibrosis or stability; Ishak F6, improvement) between the emricasan (77.1%) and placebo groups (74.1%). Overall, there was no difference between the emricasan (54.5%) and placebo (60.7%) arms in the rate of fibrosis improvement alone. However, those in the pre‐specified F3‐5 subgroup had higher rates of stability or improvement in fibrosis in the emricasan group (95.2%) compared to placebo (54.6%);(P=0.01). ALT improved over the first 12 months of therapy with emricasan. ConclusionIn liver transplant recipients with recurrent HCV who achieved SVR but had residual fibrosis, overall stability in Ishak fibrosis stage was similar between emricasan and placebo groups at 24 months (p=NS). However, there was improvement and/or stability in fibrosis stage in the pre‐specified F3‐F5 subgroup with emricasan vs. placebo (p=0.01), suggesting that patients with moderate fibrosis may further benefit with emricasan. Over 24 months, in combination with immunosuppression, tolerability and safety profiles were similar in both groups.

gastroenterology & hepatology,surgery,transplantation